"One year it’s in one country, the next year it’s in another"
In addition to continued problems on the important markets in the UK and the US, Coloplast has also experienced pricing pressure in several segments on another market. The group’s CFO calls it “one of the greatest risks we have seen historically and will see going forward”.
BY STEFAN SINGH KAILAY
“We are pleased to have won market shares across all our business segments. Our wound care business is performing particularly well and we are still able to show double-digit growth in that area,” says Chief Financial Officer, Anders Lonning-Skovgaard, about developments in the third quarter of the year for Denmark’s Coloplast.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
These products will drive growth in Coloplast
For abonnenter
Coloplast lowers its guidance again
For abonnenter
Coloplast chief disappointed with guidance change
For abonnenter
